Article summary
Numinus Wellness Inc.βs (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently announced the development of a tea bag containing psilocybin for use in clinical research. If granted appropriate regulatory approvals, this could eventually be used as a treatment for clients in psychedelic-assisted therapy. Numinus strives to be at the cutting edge of psychedelic-assisted therapies that are both innovative and safe. Numinus VP, Scientific Research, Innovation & Laboratory Operations Sharan Sidhu said the Numinus team developed the Psilocybe tea bag with scientific precision in mind. The VP stated that the companyβs best-in-class team and resources allow Numinus to control the full production The post Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use appeared first on Psychedelic Chronicle.
Continue to the original publication for the complete article.